Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis

Abstract

To clarify the role of the H-Ras in vivo, we generated H-ras null mutant mice by gene targeting. In spite of the importance of the Ras in cell proliferation and differentiation, H-ras null mutant mice grew normally and were fertile. The oldest H-ras mutant mice grew to be more than 30 months old. We used the H-ras deficient mice to study the importance of the H-ras and other ras genes in the development of skin tumors induced by initiation with 7,12-dimethylbenz(a)anthracene (DMBA) followed by promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA). We showed that H-ras null mutant mice develop approximately six times less papillomas compared with wild-type littermates after 20 weeks of TPA treatment. While all papillomas examined (17 out of 17) in wild-type mice have mutations of H-ras at codon 61, 13 (62%) out of 21 papillomas in H-ras null mutant mice have mutations of K-ras gene at codon 12, 13, or 61 and another eight (38%) papillomas have no mutations in these codons of K-ras or N-ras genes. This suggests that the activation of H-ras gene is critical in the wild-type mice, but the activation of K-ras gene can replace the H-ras activation in the initiation step of skin tumor development in the H-ras deficient mice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Balmain A, Ramsden M, Bowden GT and Smith J . 1984 Nature 307: 658–660

  • Balmain A and Brown K . 1988 Adv Cancer Res 51: 147–182

  • Barbacid M . 1987 Annu Rev Biochem 56: 779–827

  • Bizub D, Wood AW and Skalka AM . 1986 Proc Natl Acad Sci USA 83: 6048–6052

  • Boutwell RK . 1974 CRC Crit Rev Toxicol 2: 419–443

  • Bradley A . 1987 Teratocarcinomas and Embryonic Stem Cells A Practical Approach Robertson EJ ed IRL Press London pp 113–151

  • Brookes P, Cooper CS, Ellis MV, Warren W, Gardner E and Summerhayes IC . 1988 Mol Carcinog 1: 82–88

  • Brown K, Buchamann A and Balmain A . 1990 Proc Natl Acad Sci USA 87: 538–542

  • Guerrero I and Pellicer A . 1987 Mutat Res 185: 293–308

  • Harvey JJ . 1964 Nature 204: 1104–1105

  • Hecker E, Fusenig NE, Kunz W, Marks F and Thielmann HW eds . 1982 Carcinogenesis A Comprehensive Survey Raven Press New York

    Google Scholar 

  • Kemp CJ, Donehower LA, Bradley A and Balmain A . 1993 Cell 74: 813–822

  • Kirsten WH and Mayer LA . 1967 J Natl Cancer Inst 39: 311–335

  • Koera K, Nakamura K, Nakao K, Miyoshi J, Toyoshima K, Hatta T, Otani H, Aiba A and Katsuki M . 1997 Oncogene 15: 1151–1159

  • Kuehn MR, Bradley A, Robertson EJ and Evans MJ . 1987 Nature 326: 295–298

  • Lowy DR and Willumsen BM . 1993 Annu Rev Biochem 62: 851–891

  • Manam S, Storer RD, Prahalada S, Leander KR, Kraynak AR, Ledwith BJ, van Zwieten MJ, Bradley MO and Nichols WW . 1992 Cancer Res 52: 3347–3352

  • Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G and Balkwill F . 1999 Nat Med 5: 828–831

  • Quintanilla M, Brown K, Ramsden M and Balmain A . 1986 Nature 322: 78–80

  • Saez E, Rutberg SE, Mueller E, Oppenheim H, Smoluk J, Yuspa SH and Spiegelman BM . 1995 Cell 82: 721–732

  • Sekiya T, Fushimi M, Hori H, Hirohashi S, Nishimura S and Sugimura T . 1984 Proc Natl Acad Sci USA 81: 4771–4775

  • Shimizu K, Goldfarb M, Suard Y, Perucho M, Li Y, Kamata T, Feramisco J, Stanvnezer E, Fogh J and Wigler MH . 1983 Proc Natl Acad Sci USA 80: 2112–2116

  • Yagi T, Ikawa Y, Yoshida K, Shigetani Y, Takeda N, Mabuchi I, Yamamoto T and Aizawa S . 1990 Proc Natl Acad Sci USA 87: 9918–9922

  • Yuspa SH and Poirier MC . 1988 Adv Cancer Res 50: 25–70

  • Yuspa SH . 1994 Cancer Res 54: 1178–1189

  • Zarbl H, Sukumar S, Arthur AV, Martin-Zanca D and Barbacid M . 1985 Nature 315: 382–385

Download references

Acknowledgements

This work was supported in part by Grants-in-Aid for Scientific Research on Priority Areas, for Cancer Research and for Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan, Grants-in-Aid from the Ministry of Health and Welfare, Japan. We also thank K Katsuki and Y Ikeda for their excellent technical assistance and K Tsurui and T Kohyama for their help in maintaining the animals.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ise, K., Nakamura, K., Nakao, K. et al. Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 19, 2951–2956 (2000). https://doi.org/10.1038/sj.onc.1203600

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203600

Keywords

This article is cited by

Search

Quick links